ARTES received next grant of patent for METAVAX®

ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-par­ti­cle (VLP) tech­nol­o­gy plat­form METAVAX®.

The new patent inte­grates exact­ly in our exist­ing patent port­fo­lio and will fur­ther strength­en our tech­nol­o­gy offer”, said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES. “In com­bi­na­tion with our pro­pri­etary yeast expres­sion tech­nol­o­gy our anti­gen pre­sen­ta­tion plat­form METAVAX® is an excel­lent and unique tool for the devel­op­ment of effec­tive, safe and afford­able vac­cines.”

Cur­rent­ly, the plat­form METAVAX® is used in sev­er­al clients’ projects as well as in sev­er­al in-house research projects. With­in the “Pluri­vax” project, fund­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) as part of the 8th Euro­Trans­Bio call, ARTES enhances its VLP based vac­cine plat­form METAVAX® and devel­ops process­es espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions.

Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. With this new patent, we have addi­tion­al rein­force­ment to our exist­ing patent estate,” said Dr. Melanie Pio­ntek.